Physician profile
Christopher Levert
NPI 1336594878
$5,973.87
in general payments reported to CMS, 2019-2025
24 companies · $1,341 in 2025
The $1,341 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $298 · 2021: $815 · 2022: $1,136 · 2023: $1,144 · 2024: $1,240 · 2025: $1,341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,725.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,724.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,614.43 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $950.16 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $705.06 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $652.21 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Abbott Laboratories | $520.24 | 2020-2025 | Freestyle Libre 3 |
| Pfizer INC. | $385.27 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $246.37 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Dexcom, INC. | $156.35 | 2024-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $140.87 | 2023-2025 | Cologuard Collection Kit |
| Cranial Technologies, INC | $124.04 | 2021-2025 | Doc Band |
| Merck Sharp & Dohme LLC | $76.83 | 2021-2025 | Vaxelis, Vaxneuvance, Gardasil 9 |
| Bayer Healthcare Pharmaceuticals INC. | $68.83 | 2025 | |
| Glaxosmithkline, LLC. | $67.05 | 2021-2025 | Shingrix, Arexvy |
| Ibsa Pharma INC. | $45.83 | 2022-2024 | Licart, Tirosint |
| Biohaven Pharmaceutical Holding Company Ltd. | $32.04 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $30.64 | 2024-2025 | Contrave |
| Viiv Healthcare Company | $25.27 | 2025 | Apretude |
| Corium, LLC | $22.35 | 2022 | |
| Sanofi-Aventis U.S. LLC | $21.52 | 2025 | |
| Sanofi Pasteur INC. | $21.00 | 2022 | |
| Supernus Pharmaceuticals, INC. | $18.39 | 2022 | |
| Medtronic, INC. | $17.74 | 2025 | Venaseal |
| Inspire Medical Systems, INC. | $16.65 | 2024 | Inspire |
| Phadia US INC. | $14.73 | 2025 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Levert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.